| Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis H Makishima, V Visconte, H Sakaguchi, AM Jankowska, S Abu Kar, ... Blood, The Journal of the American Society of Hematology 119 (14), 3203-3210, 2012 | 491 | 2012 |
| Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms AM Jankowska, H Szpurka, RV Tiu, H Makishima, M Afable, J Huh, ... Blood, The Journal of the American Society of Hematology 113 (25), 6403-6410, 2009 | 462 | 2009 |
| Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML LP Gondek, R Tiu, CL O'Keefe, MA Sekeres, KS Theil, JP Maciejewski Blood, The Journal of the American Society of Hematology 111 (3), 1534-1542, 2008 | 403 | 2008 |
| Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms F Traina, V Visconte, P Elson, A Tabarroki, AM Jankowska, E Hasrouni, ... Leukemia 28 (1), 78-87, 2014 | 376 | 2014 |
| Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A AM Jankowska, H Makishima, RV Tiu, H Szpurka, Y Huang, F Traina, ... Blood, The Journal of the American Society of Hematology 118 (14), 3932-3941, 2011 | 365 | 2011 |
| Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2 … CN Harrison, N Schaap, AM Vannucchi, JJ Kiladjian, RV Tiu, P Zachee, ... The Lancet Haematology 4 (7), e317-e324, 2017 | 335 | 2017 |
| Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation H Szpurka, R Tiu, G Murugesan, S Aboudola, ED Hsi, KS Theil, ... Blood 108 (7), 2173-2181, 2006 | 295 | 2006 |
| SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts V Visconte, H Makishima, A Jankowska, H Szpurka, F Traina, A Jerez, ... Leukemia 26 (3), 542-545, 2012 | 276 | 2012 |
| Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies H Makishima, H Cazzolli, H Szpurka, A Dunbar, R Tiu, J Huh, ... Journal of clinical oncology 27 (36), 6109-6116, 2009 | 248 | 2009 |
| Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies RV Tiu, LP Gondek, CL O'Keefe, P Elson, J Huh, A Mohamedali, ... Blood, The Journal of the American Society of Hematology 117 (17), 4552-4560, 2011 | 238 | 2011 |
| Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms SA Wang, RP Hasserjian, PS Fox, HJ Rogers, JT Geyer, ... Blood, The Journal of the American Society of Hematology 123 (17), 2645-2651, 2014 | 227 | 2014 |
| Novel homo-and hemizygous mutations in EZH2 in myeloid malignancies H Makishima, AM Jankowska, RV Tiu, H Szpurka, Y Sugimoto, Z Hu, ... Leukemia 24 (10), 1799-1804, 2010 | 223 | 2010 |
| SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes V Visconte, HJ Rogers, J Singh, J Barnard, M Bupathi, F Traina, ... Blood, The Journal of the American Society of Hematology 120 (16), 3173-3186, 2012 | 219 | 2012 |
| An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults MR Savona, L Malcovati, R Komrokji, RV Tiu, TI Mughal, A Orazi, ... Blood, The Journal of the American Society of Hematology 125 (12), 1857-1865, 2015 | 195 | 2015 |
| Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes MA Sekeres, RV Tiu, R Komrokji, J Lancet, AS Advani, M Afable, ... Blood, The Journal of the American Society of Hematology 120 (25), 4945-4951, 2012 | 169 | 2012 |
| Application of array‐based whole genome scanning technologies as a cytogenetic tool in haematological malignancies JP Maciejewski, RV Tiu, C O’Keefe British journal of haematology 146 (5), 479-488, 2009 | 165 | 2009 |
| Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders V Visconte, H Makishima, JP Maciejewski, RV Tiu Leukemia 26 (12), 2447-2454, 2012 | 151 | 2012 |
| Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia MG Afable, M Shaik, Y Sugimoto, P Elson, M Clemente, H Makishima, ... Haematologica 96 (9), 1269, 2011 | 149 | 2011 |
| Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy RZ Mahfouz, A Jankowska, Q Ebrahem, X Gu, V Visconte, A Tabarroki, ... Clinical cancer research 19 (4), 938-948, 2013 | 148 | 2013 |
| Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia N Daver, AE Perl, J Maly, M Levis, E Ritchie, M Litzow, J McCloskey, ... Journal of Clinical Oncology 40 (35), 4048-4059, 2022 | 147 | 2022 |
Anna M. Jankowska, PhDCleveland Clinic, IUPUI, Eli Lilly and CompanyEmail verificata su iupui.edu
